Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (61-70 of 306) with videos related to

Pageof 31
Sort By:
Expert Opinion on Emerging Drugs|July 21, 2020
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonistsRaj A Shah, Naim Alkhouri, Kris V Kowdley
Digestive Diseases and Sciences|March 29, 2021
Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 DiabetesNabil Noureddin, Mazen Noureddin, Amandeep Singh, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2024
Editorial: Decoding the enigma-Navigating complexity in MASLD management. Authors' replyNaim Alkhouri, Anne-Cécile V Bayne, Naga Chalasani
Expert Review of Gastroenterology & Hepatology|August 14, 2009
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equalNaim Alkhouri, Laura J Dixon, Ariel E Feldstein
Expert Opinion on Investigational Drugs|February 28, 2025
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologistsNaim Alkhouri, Michael Charlton, Meagan Gray, et al.
Hepatology Communications|May 15, 2023
Wilson disease: a summary of the updated AASLD Practice GuidanceNaim Alkhouri, Regino P Gonzalez-Peralta, Valentina Medici
European Journal of Gastroenterology & Hepatology|January 28, 2014
Hematocrit levels and red blood cell indices in patients with nonalcoholic fatty liver diseaseDanny Issa, Mazen Albeldawi, Rocio Lopez, et al.
Hepatology Communications|September 9, 2021
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?Naim Alkhouri, Monica Tincopa, Rohit Loomba, et al.
Journal of Clinical Gastroenterology|June 16, 2009
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver diseaseNaim Alkhouri, Rocio Lopez, Michael Berk, et al.
Hepatology (Baltimore, Md.)|August 7, 2020
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic LightsNabil Noureddin, Naim Alkhouri, Kimberly A Brown, et al.
Pageof 31

Showing results (61-70 of 306) with videos related to

Sort By:
Pageof 31
Expert Opinion on Emerging Drugs|July 21, 2020
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonistsRaj A Shah, Naim Alkhouri, Kris V Kowdley
Digestive Diseases and Sciences|March 29, 2021
Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 DiabetesNabil Noureddin, Mazen Noureddin, Amandeep Singh, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2024
Editorial: Decoding the enigma-Navigating complexity in MASLD management. Authors' replyNaim Alkhouri, Anne-Cécile V Bayne, Naga Chalasani
Expert Review of Gastroenterology & Hepatology|August 14, 2009
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equalNaim Alkhouri, Laura J Dixon, Ariel E Feldstein
Expert Opinion on Investigational Drugs|February 28, 2025
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologistsNaim Alkhouri, Michael Charlton, Meagan Gray, et al.
Hepatology Communications|May 15, 2023
Wilson disease: a summary of the updated AASLD Practice GuidanceNaim Alkhouri, Regino P Gonzalez-Peralta, Valentina Medici
European Journal of Gastroenterology & Hepatology|January 28, 2014
Hematocrit levels and red blood cell indices in patients with nonalcoholic fatty liver diseaseDanny Issa, Mazen Albeldawi, Rocio Lopez, et al.
Hepatology Communications|September 9, 2021
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?Naim Alkhouri, Monica Tincopa, Rohit Loomba, et al.
Journal of Clinical Gastroenterology|June 16, 2009
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver diseaseNaim Alkhouri, Rocio Lopez, Michael Berk, et al.
Hepatology (Baltimore, Md.)|August 7, 2020
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic LightsNabil Noureddin, Naim Alkhouri, Kimberly A Brown, et al.
Pageof 31